Nurix.png
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
June 16, 2024 05:30 ET | Nurix Therapeutics, Inc.
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and...
ADV ACT logo color.jpg
Occlusion Perfusion Catheter Demonstrates Superior Performance in PAD Drug Delivery
November 02, 2023 08:28 ET | Advanced Catheter Therapies
Researchers successfully demonstrate the delivery of liquid sirolimus into the arterial wall using the OPC, which can also be used for paclitaxel BTK.
TIP_link_300x300.jpg
Coronary Stents Market worth $13.87 Billion by 2025 - Exclusive Report by The Insight Partners
September 13, 2023 09:23 ET | The Insight Partners
Pune, India, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Coronary stents are a kind of little mesh metal tubes that are developed for providing support to the weakened arteries within the heart. The coronary...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Enters Into Binding Term Sheet to Acquire Exclusive Rights to Abivertinib with Completed Registrational Trial Data in Non-Small Cell Lung Cancer
May 21, 2020 07:00 ET | Sorrento Therapeutics, Inc.
Novel TKI compound with dual selective targeting of mutant forms of EGFR and BTKMore than 600 patients have been treated with the compound across studies, with over 200 patients in the completed...
ArQule Announces $15
ArQule Announces $15.3 Million Registered Direct Offering of Common Stock
February 29, 2016 06:55 ET | ArQule, Inc.
BURLINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced it has entered into definitive agreements with certain institutional and accredited investors to raise...